Skip to main content

Table 1 Baseline Demographics and Migraine Characteristics

From: Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA

  N = 395
Gender (female) 85.1%
Age (mean, years ± SD) 46.7 ± 12.6
Aura 28.6%
Migraine duration (mean, years ± SD) 28.6 ± 15.0
Chronification time (mean, years ± SD) 10.5 ± 9.9
Headache frequency (days/month ± SD) 26.5 ± 5.2
Moderate-Severe headache frequency (days/month ± SD) 12.7 ± 7.5
Moderate-Severe headache monthly rate (% ± SD) 49.0 ± 27.6
Acute treatment (% of use) 95.7%
 NSAIDs 54.6%
 Triptans 46.1%
 Other analgesics 36.3%
Analgesic use (mean, tablets/month ± SD) 42.2 ± 42.4
Daily use of analgesic 38.7%
Medication overuse 61.3%
Stable concomitant preventive treatment (%) 77.0%
 Neuromodulators 39.2%
 Betablockers 14.9%
 Antidepressants 61.5%
 Others 10.6%
MIDAS disability category
 None 5.6%
 Mild 4.8%
 Moderate 6.8%
 Severe 82.8%
MIDAS score (mean ± SD) 82.6 ± 64.6
  1. Abbreviations: SD standard deviation, NSAID Nonsteroidal anti-inflammatory drugs, MIDAS Migraine Disability Assessment
\